Monoclonal antibody makers should consider swapping batch for continuous production, according to research suggesting new tech has made switching less of a risky endeavor. The study looked at the benefits of converting downstream processes and found that if done properly, swapping to continuous mode has a positive impact on output, time to market, and profitability.
The team used two unit operations–protein A capture chromatography and ultrafiltration—as models and found that continuous mode achieved a 28% productivity improvement. In addition, total process time was cut from four days to less than 24 hours.
